Abstract | BACKGROUND: METHODS: The study involved 13 cases of patients diagnosed with CML carrying cytogenetic abnormalities in their Ph-negative cell population after imatinib treatment. The presence of the markers within the CD34+ stem cell compartment and the cell culture growth were analyzed and patients were followed over time. RESULTS: CD34+ cells express the cytogenetic markers present in Ph- cells, suggesting a possible involvement of the stem cell population. Cultured cells showed normal growth in all but 1 patient. No growth advantage was demonstrated for the Ph-negative or the Ph-positive clone after cell culture. CONCLUSIONS: After follow-up of up to 49 months, none of the patients had evolved to myelodysplasia or acute leukemia. Hypothesis regarding the biological and clinical significance of these abnormalities are formulated.
|
Authors | Elisabetta Abruzzese, Alessandro Gozzetti, Sara Galimberti, Malgorzata Monika Trawinska, Tommaso Caravita, Agostina Siniscalchi, Giulia Cervetti, Alessandro Mauriello, Angela Maria Coletta, Paolo De Fabritiis |
Journal | Cancer
(Cancer)
Vol. 109
Issue 12
Pg. 2466-72
(Jun 15 2007)
ISSN: 0008-543X [Print] United States |
PMID | 17503437
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2007 American Cancer Society. |
Chemical References |
- Antineoplastic Agents
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- Protein-Tyrosine Kinases
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Benzamides
- Cell Separation
- Cells, Cultured
- Chromosome Aberrations
- Female
- Humans
- Imatinib Mesylate
- In Situ Hybridization, Fluorescence
- Karyotyping
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
(drug therapy, genetics, pathology)
- Male
- Metaphase
- Middle Aged
- Piperazines
(therapeutic use)
- Prognosis
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrimidines
(therapeutic use)
|